Quantum Biopharma (QNTM) Competitors $12.25 +0.93 (+8.22%) Closing price 04:00 PM EasternExtended Trading$11.75 -0.50 (-4.08%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends QNTM vs. MNOV, ANRO, SKYE, SLS, INZY, ORMP, ASMB, IMUX, MRSN, and CTORShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include MediciNova (MNOV), Alto Neuroscience (ANRO), Skye Bioscience (SKYE), SELLAS Life Sciences Group (SLS), Inozyme Pharma (INZY), Oramed Pharmaceuticals (ORMP), Assembly Biosciences (ASMB), Immunic (IMUX), Mersana Therapeutics (MRSN), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical preparations" industry. Quantum Biopharma vs. MediciNova Alto Neuroscience Skye Bioscience SELLAS Life Sciences Group Inozyme Pharma Oramed Pharmaceuticals Assembly Biosciences Immunic Mersana Therapeutics Citius Oncology Quantum Biopharma (NASDAQ:QNTM) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership. Do insiders & institutionals have more ownership in QNTM or MNOV? 1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 14.9% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is QNTM or MNOV more profitable? MediciNova's return on equity of -17.55% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -84.21% -62.63% MediciNova N/A -17.55%-16.62% Does the media prefer QNTM or MNOV? In the previous week, Quantum Biopharma had 11 more articles in the media than MediciNova. MarketBeat recorded 12 mentions for Quantum Biopharma and 1 mentions for MediciNova. MediciNova's average media sentiment score of 0.30 beat Quantum Biopharma's score of 0.00 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, QNTM or MNOV? MediciNova has higher revenue and earnings than Quantum Biopharma. MediciNova is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$17.90M-$15.41-0.79MediciNova$1M91.72-$8.56M-$0.21-8.90 Does the MarketBeat Community prefer QNTM or MNOV? MediciNova received 210 more outperform votes than Quantum Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformQuantum BiopharmaN/AN/AMediciNovaOutperform Votes21048.17% Underperform Votes22651.83% Do analysts rate QNTM or MNOV? MediciNova has a consensus target price of $9.00, suggesting a potential upside of 381.28%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, QNTM or MNOV? Quantum Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. SummaryMediciNova beats Quantum Biopharma on 13 of the 15 factors compared between the two stocks. Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.52M$6.92B$5.69B$9.04BDividend YieldN/A2.91%5.30%4.01%P/E Ratio-0.799.6589.7819.46Price / SalesN/A324.021,038.3174.18Price / CashN/A75.4646.0638.79Price / Book0.585.635.134.78Net Income-$17.90M$123.93M$113.50M$222.19M7 Day Performance285.22%-0.20%0.42%1.42%1 Month Performance246.05%-0.44%3.65%2.91%1 Year PerformanceN/A5.40%22.50%20.50% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum BiopharmaN/A$12.25+8.2%N/AN/A$23.52MN/A-0.79N/ANews CoverageGap DownMNOVMediciNova1.8642 of 5 stars$1.87flat$9.00+381.3%+32.2%$91.72M$1M-8.9010ANROAlto Neuroscience1.7901 of 5 stars$3.40-7.0%$20.00+489.1%-77.9%$91.56MN/A0.00N/ASKYESkye Bioscience1.3074 of 5 stars$3.39+24.1%$18.67+451.0%-50.4%$90.41MN/A0.0011Gap UpSLSSELLAS Life Sciences Group0.2697 of 5 stars$1.28-6.6%N/A+76.2%$90.09M$1M-1.8610Gap UpINZYInozyme Pharma3.376 of 5 stars$1.40-3.4%$18.33+1,209.5%-75.1%$89.94MN/A-0.9050Gap DownORMPOramed Pharmaceuticals1.4531 of 5 stars$2.17flatN/A-23.9%$87.47M$1.34M19.7310Positive NewsGap DownASMBAssembly Biosciences3.6135 of 5 stars$13.66+2.8%$35.00+156.2%+9.7%$86.88M$7.16M0.00100IMUXImmunic3.5676 of 5 stars$0.96-0.1%$12.67+1,219.3%-21.3%$86.49MN/A-0.7870Analyst DowngradeGap UpMRSNMersana Therapeutics4.21 of 5 stars$0.70-6.7%$5.57+695.9%-80.7%$86.47M$34.84M-1.15150Analyst RevisionCTORCitius OncologyN/A$1.20+1.7%$3.00+150.0%N/A$85.86MN/A0.00N/A Related Companies and Tools Related Companies MediciNova Alternatives Alto Neuroscience Alternatives Skye Bioscience Alternatives SELLAS Life Sciences Group Alternatives Inozyme Pharma Alternatives Oramed Pharmaceuticals Alternatives Assembly Biosciences Alternatives Immunic Alternatives Mersana Therapeutics Alternatives Citius Oncology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QNTM) was last updated on 2/10/2025 by MarketBeat.com Staff From Our PartnersNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored5-Second Trump Clip will Give You ChillsPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill O’Reilly: “the best-prepared president in history.”"We're going to bring back the American Dream... bigger, better, bolder, richer, safer, and stronger than ever...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
